
Welcome to America, Where You Can Buy a Company—But Not Run It
The Nippon Steel deal may be remembered as a turning point not just for industrial policy, but for how the U.S. is perceived by global investors. In a geopolitical moment defined by economic competition and fragmented alliances, the U.S. must choose: will it lead by example as an open, rules-based economy or slide into the very model of conditional capitalism it has long criticized in others?
The golden share may be strategic. But unless applied with extreme caution, it could prove to be short-sighted, self-defeating, and a poor trade for long-term investment leadership.

What Makes a Healthcare Startup Attractive to VCs and Private Equity?
So far in 2025, Pittsburgh-based healthcare startup Abridge has landed $250 million in funding, UK-based OrganOx closed $142 million, and Transcarent merged with Accolade, Inc.. Both Transcarent and Datavant appear to be open to additional acquisitions as they build toward IPO. Meanwhile, healthcare investors and several healthcare mega-companies have signaled that they "don't much of an appetite" for big deals this year according to Business Insider.
What does this mean? Let's figure this out!